Irhythm Holdings, Inc. · NASDAQ:IRTC
Irhythm — iRhythm Technologies — 41st Annual J.P. Morgan Healthcare Conference (January 2023)
18 slides from Irhythm's conference presentation, Jan 10, 2023
Slide 1: 41st Annual J.P. Morgan Healthcare Conference
41st Annual J.P. Morgan Healthcare Conference January 10, 2023
Slide 2: Safe Harbor
Safe Harbor Certain data in this presentation was obtained from various external sources, and neither “iRhythm” or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those “Company” nor its affiliates or representatives has verified such dat
Slide 3: 5+ Million Patients served; ~25% penetration in core market
5+ Million >30% Patients served Five-year revenue CAGR ~25% ~1.5 Million Penetration in core Patients served U.S. ambulatory cardiac annually and growing monitoring market a 35+ 66 Peer-reviewed Countries and states where we publications have employees 1 Billion Hours of curated 1,700+ ECG data Glob
Slide 4: The Zio platform enables us to address the challenges of tomorrow
The Zio platform enables us to address the challenges of tomorrow 1 2 3 PATENTED WEARABLE AI PLATFORM ACTIONABLE AND SCALABLE BIOSENSORS (34-LAYER DEEP NEURAL NET) DIGITAL PLATFORM Single-use monitor that 2nd Generation, FDA-cleared, High-quality digital patients prefer deep-learned report delivered
Slide 5: Cardiac arrhythmia burden in the U.S. is immense
Cardiac arrhythmia burden in the U.S. is immense PREVALENCE CONSEQUENCES 11M 5x with Increased risk of stroke arrhythmias due to Atrial Fibrillation (AFib) 40% 130,000 Lifetime risk of AFib Deaths per year for individuals over 55 associated with AFib FINANCIAL BURDEN 750,000 $34B Hospitalizations pe
Slide 6: Substantial and growing market potential
Substantial and growing market potential CORE U.S. EXPANSION EXPANSION MARKET OPPORTUNIT Y IN OPPORTUNIT Y IN AT-RISK INTERNATIONAL SYMPTOMATIC MARKET POPULATION SLEEP APNEA 5.6M Ambulatory cardiac 14M+ Primary care patients with 12M+ Individuals in the U.S. with HEART FAILURE monitoring tests annua
Slide 7: Differentiated platform technology with catalyst-rich pipeline
Differentiated platform technology with catalyst-rich pipeline 2023 2024 Zio Monitor Limited Market Release Zio Monitor US Commercial Launch Zio Monitor Launch into International Markets Zio MCT US Commercial Launch Zio Watch Market Evaluation: IRB Use & Clinical Studies Commercial Pilots Commercial
Slide 8: Introducing the Zio monitor
Introducing the Zio® monitor Limited market release in the U.S., FDA cleared with strong initial performance New breathable and 72% smaller 55% lighter 20% thinner waterproof outer layer Smaller refers to reduced volume. All comparisons relative to Zio® XT. Design verification data on file. iRhythm
Slide 9: Significant Zio market opportunity in the U.S.
CORE U.S. MARKE T Significant Zio® market opportunity in the U.S. US PATIENT POPULATION 213 • >20 years old (excludes non-insured population) million • Source: US Census Bureau2 UNIQUE PCP VISITS • Average ~2.8 physician visits annually 200 • 51% are PCP visits million • IRTC estimates ~200M unique
Slide 10: Broad access achieved through commercial and government payers
Broad access achieved through commercial and government payers Most major commercial plans cover Zio® XT and Zio® AT1 Medicare coverage available for Zio® XT and Zio® AT nationwide2 Medicare national pricing established for Zio® XT via 2023 Physician Fee Schedule Final Rule3 1. Includes Medicare Adv
Slide 11: OUS opportunity represents $1+ billion with 5+ million TAM in prioritized countries
INTE RNATION A L E XPANSION OUS opportunity represents $1+ billion with 5+ million TAM in prioritized countries across EMEA and Asia Pacific PRIORITIZED EU COUNTRIES Switzerland, Spain, Sweden, the Netherlands, Germany and France UNITED KINGDOM Initiating market access efforts in JAPAN Early commerc
Slide 12: The ground-breaking program for early detection of heart arrhythmias
ADJACE NT MARKE TS INTRODUCING The ground-breaking program for early detection of heart arrhythmias. © 2023 iRhythm Technologies, Inc. 12
Slide 13: Zio XT provides high value from health economic perspective
KNOW YOUR RHYTHM ® Zio XT provides high value from health economic perspective ICER fixed cost effectiveness thresholds for diagnostic interventions ® Zio XT demonstrated gain in quality- HIGH VALUE INTERMEDIATE VALUE LOW VALUE adjusted life expectancy while providing excellent value to healthcare s
Slide 14: Significant adjacent market opportunities
Significant adjacent market opportunities SLEEP APNEA HEART FAILURE HYPERTENSION 2022 prevalence1: 40.1M 2022 prevalence1: 8.4M 2022 prevalence1: 166.0M Up to 80% of AF patients have 25% of heart failure patients Up to 90% of AF patients have sleep apnea have AF hypertension and there is a large com
Slide 15: Significant accomplishments and investments in 2022 provide the foundation for sustained high growth
Significant accomplishments and investments in 2022 provide the foundation for sustained high growth over the long term ENABLING MARKET ACCELERATING EXPANSION OPPORTUNITIES INNOVATION • Record number of new Zio® XT account • FDA clearance of 2nd generation algorithm openings • Zio® monitor limited m
Slide 16: Addressing the future focus of healthcare
Addressing Expanding the future focus existing markets of healthcare while extending into adjacent markets Out-paced Delivering revenue growth meaningful from massive improvements in underpenetrated financial profile markets on a global scale
Slide 17: Appendix
iIRHYTHM Appendix
Slide 18: Sources
Sources SLIDE SOURCES Cardiac arrhythmia burden Morillo, C., et al. Atrial fibrillation: the current epidemic. Journal of Geriatric Cardiology, 2017; Circulation, 2018;137:1027-38; Rienstra, in the U.S. is immense M., et al. Symptoms and functional status of patients with atrial fibrillation. Circul
iRhythm Technologies — 41st Annual J.P. Morgan Healthcare Conference (January 2023) on 6ix